

Title (en)
A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT FETTSUCHT MIT EINEM INSULINOTROPEN PEPTID-KONJUGAT

Title (fr)
COMPOSITION PHARMACEUTIQUE POUR TRAITER UNE MALADIE LIÉE À L'OBÉSITÉ CONTENANT UN CONJUGUÉ DE PEPTIDE INSULINOTROPIQUE

Publication
EP 2227243 A4 20120509 (EN)

Application
EP 08855148 A 20081128

Priority

- KR 2008007074 W 20081128
- US 94769707 A 20071129
- KR 20080083194 A 20080826

Abstract (en)
[origin: WO2009069983A2] The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

IPC 8 full level
A61K 38/16 (2006.01); **A61K 31/365** (2006.01); **A61K 38/22** (2006.01); **A61K 38/26** (2006.01); **A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61P 3/04** (2006.01)

CPC (source: EP KR)
A61K 31/137 (2013.01 - EP); **A61K 31/74** (2013.01 - KR); **A61K 38/16** (2013.01 - KR); **A61K 38/22** (2013.01 - EP); **A61K 38/2207** (2013.01 - EP); **A61K 38/26** (2013.01 - EP); **A61K 47/6811** (2017.07 - EP); **A61K 47/6835** (2017.07 - EP); **A61K 47/6889** (2017.07 - EP); **A61P 1/00** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/50** (2017.12 - EP); **A61P 9/00** (2017.12 - EP)

Citation (search report)

- [XP] WO 2008082274 A1 20080710 - HANMI PHARMACEUTICAL CO LTD [KR], et al
- [XY] WO 2006107124 A1 20061012 - HANMI PHARMACEUTICAL CO LTD [KR], et al
- [XY] WO 2005047334 A1 20050526 - HANMI PHARM IND CO LTD [KR], et al
- See references of WO 2009069983A2

Cited by
WO2014161835A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2009069983 A2 20090604; WO 2009069983 A3 20090820; AR 069458 A1 20100120; AU 2008330315 A1 20090604; AU 2008330315 B2 20120621; BR PI0819864 A2 20170523; CA 2706627 A1 20090604; CA 2706627 C 20141118; CN 101878036 A 20101103; CN 101878036 B 20140514; DK 2227243 T3 20141006; EP 2227243 A2 20100915; EP 2227243 A4 20120509; EP 2227243 B1 20140813; ES 2521497 T3 20141112; HK 1150029 A1 20111028; HR P20140997 T1 20141219; IL 205667 A0 20101130; IL 205667 A 20161130; JP 2011505355 A 20110224; JP 5226080 B2 20130703; KR 101135244 B1 20120424; KR 20090056796 A 20090603; MX 2010005866 A 20100623; MY 155454 A 20151015; NZ 585314 A 20121026; PL 2227243 T3 20150331; PT 2227243 E 20141022; RU 2010126478 A 20120110; RU 2446816 C2 20120410; TW 200936154 A 20090901; TW I403331 B 20130801; ZA 201003796 B 20110223

DOCDB simple family (application)
KR 2008007074 W 20081128; AR P080105187 A 20081128; AU 2008330315 A 20081128; BR PI0819864 A 20081128; CA 2706627 A 20081128; CN 200880118353 A 20081128; DK 08855148 T 20081128; EP 08855148 A 20081128; ES 08855148 T 20081128; HK 11104223 A 20110427; HR P20140997 T 20141017; IL 20566710 A 20100510; JP 2010535887 A 20081128; KR 20080083194 A 20080826; MX 2010005866 A 20081128; MY PI20102321 A 20081128; NZ 58531408 A 20081128; PL 08855148 T 20081128; PT 08855148 T 20081128; RU 2010126478 A 20081128; TW 97145881 A 20081127; ZA 201003796 A 20100527